

- 12 -

**Patent claims**

1. Pharmaceutical composition suited for administration by inhalation, which comprises roflumilast and an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts together with pharmaceutically acceptable excipients and/or carriers in a fixed or free combination.
2. Pharmaceutical composition according to claim 1, which is a fixed combination.
3. Pharmaceutical composition according to claim 1, which is a free combination.
4. A pharmaceutical composition according to claim 1, 2 or 3 wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.
5. A pharmaceutical composition according to claim 1, 2 or 3 wherein the anticholinergic agent is ipratropium bromide.
6. A pharmaceutical composition according to claim 1, 2 or 3, wherein the anticholinergic agent is oxitropium bromide.
7. A pharmaceutical composition according to any of claims 1 to 6, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide.
8. A pharmaceutical composition according to any of claims 1 to 6, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxypyrid-4-yl)benzamide.
9. Method for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease by administering to a patient in need thereof by inhalation an effective amount of roflumilast and an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts, either in a single combined form, separately, or separately and sequentially, where the sequential administration is close in time or remote in time.
10. Method according to claim 9, wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.
11. Method according to claim 9, wherein the anticholinergic agent is ipratropium bromide.
12. Method according to claim 9, wherein the anticholinergic agent is oxitropium bromide.

- 13 -

**13.** Method according to any of claims 9 to 12, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide.

**14.** Method according to any of claims 9 to 12, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxyprid-4-yl)benzamide.

**15.** Method according to any of claims 9 to 14, wherein the respiratory disease is COPD.

**16.** Use of a combination of roflumilast and an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts for the preparation of a pharmaceutical composition for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease.

**17.** Use according to claim 16, wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.

**18.** Use according to claim 16, wherein the anticholinergic agent is ipratropium bromide.

**19.** Use according to claim 16, wherein the anticholinergic agent is oxitropium bromide.

**20.** Use according to any of claims 16 to 19, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide.

**21.** Use according to any of claims 16 to 19, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxyprid-4-yl)benzamide.

**22.** Use according to any of claims 16 to 21, wherein the respiratory disease is COPD.